West Family Investments Inc. Sells 4,502 Shares of Novo Nordisk A/S (NYSE:NVO)

West Family Investments Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,871 shares of the company's stock after selling 4,502 shares during the quarter. West Family Investments Inc.'s holdings in Novo Nordisk A/S were worth $1,102,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Transce3nd LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $33,000. North Capital Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Finally, Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after buying an additional 255 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.5%

NVO stock traded down $0.95 during trading hours on Friday, hitting $64.34. The company's stock had a trading volume of 6,792,977 shares, compared to its average volume of 7,369,619. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $287.27 billion, a PE ratio of 19.04, a price-to-earnings-growth ratio of 1.29 and a beta of 0.64. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $139.74. The stock has a 50 day moving average price of $70.37 and a two-hundred day moving average price of $74.53.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NVO. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.